Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 3/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.52 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504108 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAACEITGB3ITGA2B | |
| SCHEMBL27547070 | 1.00 | ALDH1A1 (0.61) | ALDH1A1LMNAACEITGB3ITGA2B | |
| Valine SCHEMBL7689739 | 0.89 | ALDH1A1 (0.51) | ALDH1A1LMNAACEITGB3ITGA2B | |
| SCHEMBL5995731 | 0.89 | MME (0.63) | ALDH1A1LMNAACEMMECPA1 | |
| SCHEMBL31688037 | 0.87 | MME (0.52) | ALDH1A1LMNAACEITGB3ITGA2B | |
| Acetyl Tyrosine SCHEMBL8977600 | 0.85 | FOLH1 (0.66) | LMNAACEITGB3ITGA2BCA2 | |
| SCHEMBL5061764 | 0.85 | LMNA (0.61) | LMNAACEITGB3ITGA2BMME | |
| Acetyl Tyrosine SCHEMBL8977601 | 0.85 | FOLH1 (0.66) | LMNAACEITGB3ITGA2BCA2 | |
| SCHEMBL14031836 | 0.85 | LMNA (0.61) | LMNAACEITGB3ITGA2BMME | |
| SCHEMBL11122115 | 0.85 | LMNA (0.61) | LMNAACEITGB3ITGA2BMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| WO-2002068586-A2 | HIV/FIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-09-06 | — | — | WO | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2021119554-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| CN-112261939-A | Granzyme B directed imaging and therapy | 塞托赛特生物制药股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3634498-A1 | LINKED AND OTHER PH-TRIGGERED COMPOUNDS | Rhode Island Council on Postsecondary Education (US) | 2020-04-15 | — | — | EP | disclosed |
| CN-1155612-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| EP-1365023-A1 | DNA ENCODING NOVEL D-AMINOACYLASE AND PROCESS FOR PRODUCING D-AMINO ACID BY USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002068586-A2 | HIV/FIV PROTEASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1185869-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | Graffinity Pharmaceutical Design GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| CN-1330076-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330077-A | Endothelin antegon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| WO-2000073796-A2 | LIGAND-ANCHOR CONJUGATES FOR PRODUCING A BIOSENSOR LAYER | GRAFFINITY PHARMACEUTICAL DESIGN GMBH (DE) | 2000-12-07 | — | — | WO | disclosed |
| US-5364850-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-11-15 | — | — | US | disclosed |
| US-5272175-A | Substituted tyrosyl diamide compounds | G. D. SEARLE & CO. (US) | 1993-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | ALDH1A1 4592/4885LMNA 783/4885ACE 1545/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | ALDH1A1 4592/4885LMNA 783/4885ACE 1545/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | ALDH1A1 4592/4885LMNA 783/4885ACE 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.